The recent FDA approval of the IsoPSA blood test may represent a notable advancement in prostate cancer screening and diagnosis. Developed by Cleveland Diagnostics, the in vitro diagnostic instrument ...

Prostate cancer is the second leading cause of cancer death in men in the U.S., with an expected 288,000 cases and 34,700 deaths expected in 2023, per the American Cancer Society. As artificial ...

Please provide your email address to receive an email when new articles are posted on . MyProstateScore 2.0 showed high sensitivity for detecting aggressive prostate cancer without the need for a ...

Novel risk stratification tool advances the frontier of precision oncology by providing access to insights informing critical on-the-ground treatment decisions Artera, the developer of multimodal ...

By A/Prof Anthony Lowe - CEO, Prostate Cancer Foundation of Australia Use of the digital rectal examination (DRE) to detect ...

Researchers have found a simple at home urine test for prostate cancer screening is highly accurate. Researchers at Vanderbilt and the University of Michigan have shown that a simple at-home urine ...

THIS YEAR, IT’S estimated that nearly 300,000 new prostate cancer cases will be diagnosed. While there’s no single test to detect prostate cancer, doctors commonly use the prostate-specific antigen ...

Levels of potential biomarkers for prostate cancer in urine were comparable after a digital rectal examination (DRE) in a physician's office and at a man's home, suggesting the feasibility of an ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug ...